Financials data is unavailable for this security.
View more
Year on year Qingdao Haier Biomedical Co Ltd 's revenues fell -20.36% from 2.86bn to 2.28bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 600.79m to 406.07m, a -32.41% decrease.
| Gross margin | 47.82% |
|---|---|
| Net profit margin | 16.34% |
| Operating margin | 17.17% |
| Return on assets | 6.56% |
|---|---|
| Return on equity | 8.41% |
| Return on investment | 8.29% |
More ▼
Cash flow in CNYView more
In 2023, Qingdao Haier Biomedical Co Ltd increased its cash reserves by 34.95%, or 325.48m. Cash Flow from Investing totalled 252.76m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 249.26m in cash from operations while cash used for financing totalled 168.30m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 13.53 |
|---|---|
| Tangible book value per share | 9.84 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.80 |
|---|---|
| Quick ratio | 2.53 |
| Total debt/total equity | 0.0344 |
|---|---|
| Total debt/total capital | 0.0316 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 14.44% while earnings per share excluding extraordinary items fell by -32.41%. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.70% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 45.41% |
| EPS growth(5 years) | 19.34 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -27.72 |
More ▼
